EPR Biotech News

Assay-Ready Chemistry Partnership between Enamine and Molplex

Molplex and Enamine today announced a new partnership to offer the Enamine screening collection of 1.8 million stock chemicals through the Molplex online drug design and assay-ready chemical supply services. The agreement is a major step towards eliminating the high start-up costs ofdrug discovery, bringing sophisticated drug design, compound management and assay-ready chemistry to ...

Drug Discovery On Demand By Molplex

An innovative new online “drug discovery on demand” platform has been launched by Molplex, a company specializing in products and services for the life sciences. Designed to help drug discovery groups working anywhere in the world, it aimsto eliminate the high start-up costs and minimize the financial risks traditionally associated ...

Website Recognizes Benefits of Biotech Crops

A new website by The United Soybean Board (USB) highlights the important role biotechnology plays in allowing U.S. farmers to continue to meet the world’s food demand as well as ensuring our environment and food supply remains as safe as ever. Whether you know it as biotech, genetically modified or ...

Welcome to EPR Biotech News

EPR Biotech News is a new blog, part of EPR Network, that is going to be focused on and will be covering the biotech news and stories from press releases published on EPR Network. EPR Network (EPR stands for express press release) is one of the nation’s largest press release distribution networks on Web. The EPR’s nationwide network includes 12 State based ...

Advinus, SignalChem Start The Multi-Year, Multi-Target Collaboration On New Anti-Cancer Drugs

Advinus Therapeutics, a research-based pharmaceutical development company promoted by the TATA Group, and SignalChem Pharmaceuticals, a British Columbia-based drug discovery company, have started working on 15 programs based on SignalChem’s proprietary Kinase platform for targeted therapies in oncology. Each program is being developed with corresponding diagnostics and tracers for patient ...

CYTOO Raises 10 M$ (7M€) in Series C Round

CYTOO SA, a company that specializes in cell-based assays, is pleased to announce the closing of a series C funding round of USD 10M (EUR 7M). New investors, Sham and Entrepreneurs Fund (EF), led the round. Existing investors AURIGA Partners and Jacques Lewiner, co-founder and president of the supervisory board ...

Search

The archives run deep. Feel free to search older content using topic keywords.